Oculis Holding AG (OCS)
NASDAQ·Healthcare·Biotechnology
$26.77
-1.29%
Mkt Cap $1.53B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Mar 3, 2026 | $142.92K | $518.43K | +262.75% | -$0.48 | -$0.51 | -6.73% | — | — |
| Q4 2025 Nov 10, 2025 | $136.87K | $305.46K | +123.18% | -$0.50 | -$0.40 | +20.00% | — | — |
| Q3 2025 Aug 21, 2025 | $143.34K | $328.48K | +129.16% | -$0.53 | -$0.59 | -11.32% | — | — |
| Q2 2025 May 8, 2025 | $217.54K | $321.94K | +47.99% | -$0.51 | -$0.77 | -50.98% | — | — |
| Q1 2025 Mar 11, 2025 | $144.16K | $3.30K | -97.71% | -$0.48 | -$0.76 | -58.33% | — | — |
| Q4 2024 Nov 7, 2024 | $260.00K | $236.01K | -9.23% | -$0.52 | -$0.55 | -5.77% | — | — |
| Q3 2024 Aug 27, 2024 | $271.97K | $273.44K | +0.54% | -$0.43 | -$0.56 | -30.23% | — | — |
| Q2 2024 May 8, 2024 | $288.67K | $245.15K | -15.07% | -$0.41 | -$0.44 | -7.32% | — | — |
| Q1 2024 Mar 18, 2024 | $280.87K | $216.21K | -23.02% | -$0.42 | -$0.38 | +9.52% | — | — |
| Q4 2023 Nov 15, 2023 | $120.93K | $238.78K | +97.45% | -$0.36 | -$0.38 | -5.56% | — | — |
| Q3 2023 Aug 29, 2023 | $195.42K | $278.72K | +42.62% | -$0.33 | -$0.38 | -15.15% | — | — |
| Q1 2023 Mar 31, 2023 | — | $261.36K | — | — | -$1.51 | — | — | — |
| Q1 2023 Mar 28, 2023 | — | $231.38K | — | — | -$0.30 | — | — | — |
| Q3 2022 Sep 30, 2022 | — | $205.28K | — | — | -$0.31 | — | — | — |
| Q2 2022 Jun 30, 2022 | — | $250.53K | — | — | -$0.39 | — | — | — |
| Q1 2022 Mar 31, 2022 | — | $267.88K | — | — | -$0.32 | — | — | — |
| Q4 2021 Dec 31, 2021 | — | $423.21K | — | — | -$0.19 | — | — | — |
| Q3 2021 Sep 30, 2021 | — | $21.48K | — | — | -$0.16 | — | — | — |